The Use Of A Multidrug Pill In Reducing Cardiovascular Events (UMPIRE) Trial
Funder
National Health and Medical Research Council
Funding Amount
$314,535.00
Summary
Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Aust ....Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Australian researchers will have a pivotal role in collecting and interpreting the data in this trial. In addition, Australian researchers will combine the findings of this study with results from similar trials being conducted in Australia (1600 patients, including 600 Aboriginal participants) and New Zealand (600 patients, including 600 Maori participants). This overview will provide very accurate information about the usefulness of the polypill, and how it should be used worldwide.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$1,477,963.00
Summary
Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a ....Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a normal protein in the blood, are another major causal risk factor for atherosclerosis (and stroke and heart attacks). Furthermore, blood concentrations of homocysteine can be lowered by about one quarter with simple, safe and inexpensive multivitamin therapy (folic acid, vitamin B12, and vitamin B6). However, despite the potentially massive public health benefits of such a strategy, it remains to be demonstrated in properly designed clinical trials that lowering homocysteine levels in the blood actually prevents stroke and heart attack. The VITATOPS trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$470,887.00
Summary
The VITAmins To Prevent Stroke (VITATOPS) trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke. To date more than 7,500 patients have been randomised. Ongoing support is requested to complete the follow-up of 8,000 patients by middle of 2009.
VITATOPS - A Randomised Controlled Trial Of Vitamins To Prevent Stroke
Funder
National Health and Medical Research Council
Funding Amount
$391,364.00
Summary
A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS ....A high level of a normal protein component in the blood (homocysteine) is fast becoming recognised as a new risk factor for premature stroke and heart disease, although it remains uncertain whether treatment with vitamins can prevent these diseases from occurring. VITATOPS is a multi-centre, double-blind, placebo-controlled trial designed to examine the efficacy and safety of multi-vitamin therapy (folate, B6 and B12) in the prevention of stroke and other types of vascular disease. The VITATOPS study arises from a large body of consistent, biologically plausible evidence linking homocysteine in a dose-dependent fashion to stroke and other types of vascular disease. A simple, non-toxic, and inexpensive intervention in the form of multivitamins (folate, B6 and B12) has been shown to be highly effective at reducing homocysteine levels, irrespective of the underlying cause. All patients who are referred to a neurologist or general physician in one of the collaborating centres within six months of a stroke or transient ischaemic attack are eligible for the trial. In total, treatment will continue for a period of between 1 and 5 years. During this time, patients will be closely monitored in order to record the occurrence of any vascular events (particularly strokes and heart attacks). Neither the study investigator nor the patient will know which treatment they are receiving (i.e. it is 'double blind'). The number of vascular events in the treatment groups will be compared at the end of the study in order to determine whether vitamin treatment is beneficial. This application is for five years of support to allow the investigators to move from the pilot phase of VITATOPS in Perth to begin recruitment to the definitive trial in other centres across Australia and New Zealand. This study may have a major impact on patient management. If vitamins prove to be effective, we may recommend vitamin supplementation to all of our stroke patients in the future.Read moreRead less
Chronic Disease Prevention In Priority Populations Via Scalable Health Behaviour Interventions
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Globally the burden of chronic disease is enormous. Smoking, risky alcohol use, inadequate fruit and vegetable intake and physical inactivity are modifiable risk factors of chronic conditions. This fellowship aims to prevent chronic diseases in priority populations who have poorer health outcomes including disadvantaged groups, those living in regional and remote areas and people born overseas by implementing and evaluating scalable health behaviour interventions to improve health outcomes.
Towards Global Control Of Scabies: Advances In Diagnosis, Treatment And Community Control
Funder
National Health and Medical Research Council
Funding Amount
$340,891.00
Summary
The scabies mite causes severe itch and rash and leads to infections, kidney and heart disease. Scabies affects up to 50% of children in Indigenous communities. We now know most scabies can be prevented, so we urgently need to find the most effective strategies. My research will develop new tests to help doctors to accurately diagnose scabies. I will test new medicines to treat scabies and strategies to prevent scabies and its complications in children, families and entire populations.
Preventing Postnatal Depression In New Mothers Using Telephone Peer Support: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$850,069.00
Summary
Depression in recent mothers are very common; more than 53,000 new mothers in Australia are affected by this each year. The condition can lead to serious adverse consequences for a mother’s health and the health of her infant and family. Effective strategies to prevent and reduce maternal depression are therefore needed. We will test whether support by telephone from other mothers (peer volunteers) helps in women at increased risk at 4 weeks postpartum.
Treatment Of Asymptomatic Candidiasis In Pregnant Women For The Prevention Of Preterm Birth: A Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,714,148.00
Summary
Prevention of early birth is a global priority. This study will establish if a simple process of screening and treating asymptomatic thrush in pregnancy prevents early birth. If positive the results of this study will change pregnancy management across the world to ensure a healthier start to life.
Evaluating The Efficacy Of An Integrated Smoking Cessation Intervention For Mental Health Patients: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,442,270.00
Summary
Smoking rates are 2 to 4 times higher among people with a mental illness than among the general population. There is an imperative to identify effective cessation interventions that can be systematically provided to smokers with a mental illness. The aim of this project is to undertake a rigorous test of the efficacy of a smoking cessation intervention for smokers with mental illness; where intervention commences in the hospital inpatient setting and extended support continues post-discharge.